Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 81
Small but growing market for anti-obesity medication in
the US
AOM Market Value has grown quickly in recent
years, fuelled by branded treatment uptake
AOM value
in mUSD
Few people treated with AOM, but in recent
years launches have fuelled market growth
Generic TRX volume
AOM TRX volume
Phentermine
1,000
and topiramate
launch
800
Branded TRX volume
Lorcaserin
launch
SaxendaⓇ
launch
700
600
500
400
300
200
100
0
2009 2010 2011 2012 2013 2014 2015 2016
Note: Values are shown in terms of Moving-Annual-Total ending August
Source: IMS NSP Monthly, August 2016
changing
diabetes
600
400
200
0
Aug
2010
Naltrexone
I HCI and
bupropion
HCI
launch
Note: Phentermine and topiramate is the fixed combination; naltrexone HCI and bupropion
HCI is the second fixed dosed combination to market. AOM: anti-obesity medication
Source: IMS NPA Monthly, August 2016
Aug
2016
novo nordiskView entire presentation